Shiva Malek

List of Publications by Year
in descending order

56 papers	5,804 citations	159358 30 h-index	168136 53 g-index
60 all docs	60 docs citations	60 times ranked	8356 citing authors

#	Article	IF	Citations
1	Biology, technology and a bit of serendipity: an interview with Shiva Malek. DMM Disease Models and Mechanisms, 2022, 15, .	1.2	1
2	RTK-Dependent Inducible Degradation of Mutant PI3KÎ± Drives GDC-0077 (Inavolisib) Efficacy. Cancer Discovery, 2022, 12, 204-219.	7.7	40
3	Structure-based optimization of hydroxylactam as potent, cell-active inhibitors of lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2022, 59, 128576.	1.0	0
4	CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Reports, 2022, 38, 110351.	2.9	18
5	Machine-Learning and Chemicogenomics Approach Defines and Predicts Cross-Talk of Hippo and MAPK Pathways. Cancer Discovery, 2021, 11, 778-793.	7.7	26
6	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a 5-Fluoro-4-(3H)-quinazolinone Aryl Urea pan-RAF Kinase Inhibitor. Journal of Medicinal Chemistry, 2021, 64, 3940-3955.	2.9	17
7	Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor. ACS Medicinal Chemistry Letters, 2021, 12, 791-797.	1.3	3
8	Emerging Trends in Cancer Drug Discoveryâ€"From Drugging the â€œUndruggableâ€•to Overcoming Resistance. Cancer Discovery, 2021, 11, 815-821.	7.7	24
9	RAS-targeted therapies. Nature Reviews Drug Discovery, 2021, , .	21.5	14
10	ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature, 2021, 594, 418-423.	13.7	64
11	The promise and peril of KRAS G12C inhibitors. Cancer Cell, 2021, 39, 1059-1061.	7.7	10
12	Dimerization Induced by C-Terminal 14â€“3â€“3 Binding Is Sufficient for BRAF Kinase Activation. Biochemistry, 2020, 59, 3982-3992.	1.2	29
13	RAS-targeted therapies: is the undruggable drugged?. Nature Reviews Drug Discovery, 2020, 19, 533-552.	21.5	569
14	Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Nature Structural and Molecular Biology, 2020, 27, 134-141.	3.6	66
15	Partners in Crime: Clandestine Operations among RAS-RAF Accomplices in Promoting Tumorigenesis. Molecular Cell, 2019, 76, 853-855.	4.5	1
16	Targeting the MAPK Pathway in RAS Mutant Cancers. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a031492.	2.9	41
17	Pharmacological Induction of RAS-GTP Confers RAF Inhibitor Sensitivity in KRAS Mutant Tumors. Cancer Cell, 2018, 34, 611-625.e7.	7.7	51
18	The RAS/MAPK Axis Gets Stressed Out. Molecular Cell, 2016, 64, 854-855.	4.5	7

#	Article	IF	Citations
19	Tissue-Specific Mutations in BRAF and EGFR Necessitate Unique Therapeutic Approaches. Trends in Cancer, 2016, 2, 699-701.	3.8	4
20	Cell Active Hydroxylactam Inhibitors of Human Lactate Dehydrogenase with Oral Bioavailability in Mice. ACS Medicinal Chemistry Letters, 2016, 7, 896-901.	1.3	41
21	Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition. Nature Chemical Biology, 2016, 12, 779-786.	3.9	180
22	Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor. Journal of Medicinal Chemistry, 2016, 59, 9080-9093.	2.9	16
23	Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2. Cancer Cell, 2016, 29, 477-493.	7.7	171
24	Pyridones as Highly Selective, Noncovalent Inhibitors of T790M Double Mutants of EGFR. ACS Medicinal Chemistry Letters, 2016, 7, 100-104.	1.3	29
25	4-Aminoindazolyl-dihydrofuro[3,4- d]pyrimidines as non-covalent inhibitors of mutant epidermal growth factor receptor tyrosine kinase. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 534-539.	1.0	42
26	Mitigation of Acetylcholine Esterase Activity in the 1,7-Diazacarbazole Series of Inhibitors of Checkpoint Kinase 1. Journal of Medicinal Chemistry, 2015, 58, 5053-5074.	2.9	14
27	Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study. Journal of Medicinal Chemistry, 2015, 58, 8877-8895.	2.9	43
28	Optimization of 5-(2,6-dichlorophenyl)-3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 75-82.	1.0	18
29	Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5704-5709.	1.0	14
30	Identification of 3,6-disubstituted dihydropyrones as inhibitors of human lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5683-5687.	1.0	17
31	Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation. Journal of Medicinal Chemistry, 2014, 57, 10176-10191.	2.9	53
32	Structure of the BRAF-MEK Complex Reveals a Kinase Activity Independent Role for BRAF in MAPK Signaling. Cancer Cell, 2014, 26, 402-413.	7.7	173
33	Identification of substituted 3-hydroxy-2-mercaptocyclohex-2-enones as potent inhibitors of human lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 3764-3771.	1.0	37
34	A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5097-5104.	1.0	26
35	Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature, 2013, 501, 232-236.	13.7	270
36	Noncovalent Wild-typeâ€“Sparing Inhibitors of EGFR T790M. Cancer Discovery, 2013, 3, 168-181.	7.7	87

#	Article	IF	Citations
37	Identification of 2-amino-5-aryl-pyrazines as inhibitors of human lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 5533-5539.	1.0	52
38	Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3186-3194.	1.0	72
39	Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349. ACS Medicinal Chemistry Letters, 2013, 4, 103-107.	1.3	43
40	Identification of Preferred Chemotherapeutics for Combining with a CHK1 Inhibitor. Molecular Cancer Therapeutics, 2013, 12, 2285-2295.	1.9	52
41	Pyrimidoaminotropanes as Potent, Selective, and Efficacious Small Molecule Kinase Inhibitors of the Mammalian Target of Rapamycin (mTOR). Journal of Medicinal Chemistry, 2013, 56, 3090-3101.	2.9	28
42	Combination Drug Scheduling Defines a â€œWindow of Opportunityâ€•for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900. Molecular Cancer Therapeutics, 2013, 12, 1968-1980.	1.9	34
43	A BRAFâ€MEK complex reveals the molecular basis of oncogenic mutations. FASEB Journal, 2013, 27, 1031.11.	0.2	0
44	Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5299-5304.	3.3	526
45	Potent, Selective, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin Kinase Domain Exhibiting Single Agent Antiproliferative Activity. Journal of Medicinal Chemistry, 2012, 55, 10958-10971.	2.9	27
46	Discovery of XL888: A novel tropane-derived small molecule inhibitor of HSP90. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5396-5404.	1.0	57
47	Potent, Selective, and Orally Bioavailable Inhibitors of Mammalian Target of Rapamycin (mTOR) Kinase Based on a Quaternary Substituted Dihydrofuropyrimidine. Journal of Medicinal Chemistry, 2011, 54, 3426-3435.	2.9	25
48	RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 2010, 464, 431-435.	13.7	1,451
49	A Plate-Based Assay to Measure Cellular ERK Substrate Phosphorylation: Utility for Drug Discovery of the MAPK-Signaling Cascade. Assay and Drug Development Technologies, 2010, 8, 497-503.	0.6	0
50	X-ray Crystal Structure of an IÎºBÎ²Â·NF-ÎºB p65 Homodimer Complex. Journal of Biological Chemistry, 2003, 278, 23094-23100.	1.6	107
51	IÎºBÎ², but Not IÎºBÎ±, Functions as a Classical Cytoplasmic Inhibitor of NF-ÎºB Dimers by Masking Both NF-ÎºB Nuclear Localization Sequences in Resting Cells. Journal of Biological Chemistry, 2001, 276, 45225-45235.	1.6	152
52	Preparation and Crystallization of Dynamic NF-ÎºBÂ·IÎºB Complexes. Journal of Biological Chemistry, 2000, 275, 32800-32806.	1.6	16
53	Mechanism of ÎºB DNA binding by Rel/NF-ÎºB dimers. Journal of Biological Chemistry, 2000, 275, 24392-24399.	1.6	120
54	The Crystal Structure of the IÎºBÎ±/NF-ÎºB Complex Reveals Mechanisms of NF-ÎºB Inactivation. Cell, 1998, 95, 759-770.	13.5	592

#	Article	IF	Citations
55	IÎºBÎ± Functions through Direct Contacts with the Nuclear Localization Signals and the DNA Binding Sequences of NF-ÎºB. Journal of Biological Chemistry, 1998, 273, 25427-25435.	1.6	148
56	Structure of G.cntdot.T.cntdot.A triplet in an intramolecular DNA triplex. Biochemistry, 1992, 31, 4838-4846.	1.2	71